Search the Newsreel

CRISIL Limited (NSE:CRISIL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

CRISPR Therapeutics (CRSP) presented at the H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, detailing strategic partnerships, pipeline progress, and financial outlook. Key highlights include a co-development deal with Sirius Therapeutics for an siRNA platform, ongoing commercialization success of Casgevy, and promising Phase I …

CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

CRISPR Therapeutics (CRSP) presented a strategic overview and portfolio highlights at the 43rd Annual J.P. Morgan Healthcare Conference. The company is focused on developing transformative gene-based medicines across four franchises, including the approved CASGEVY therapy, multiple clinical programs, and a strong financial position. They …

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 …

CRIS Q2'26 Earnings: revenue estimate is 1.00M USD

Curis, Inc. (CRIS) is scheduled to release its Q2'26 earnings on July 30, with an estimated revenue of $1.00 million and an anticipated EPS of ($6.98). The article provides a detailed table of past and estimated revenue and EPS figures for CRIS from Q2'25 …

Monashee Investment Management LLC Takes Position in CRISPR Therapeutics AG $CRSP

Monashee Investment Management LLC has initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, acquiring 50,000 shares valued at approximately $2.38 million, representing 1.3% of its portfolio. This move comes as CRISPR Therapeutics' stock has recently traded down 1.9% at …

Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs

Goldman Sachs has maintained a "Hold" rating on Crispr Therapeutics AG (CRSP) with a price target of $48.00, following the company's shares closing at $46.99. Despite a "Moderate Buy" consensus from other analysts with a higher average price target, Crispr Therapeutics reported a quarterly …

Curis reports updated trial data for emavusertib in lymphoma

Curis Inc. announced updated clinical data for its drug emavusertib in patients with Primary CNS Lymphoma, showing a 100% objective response rate in BTK-naive patients and 33% in BTKi-experienced patients. The company also provided an enrollment update for its chronic lymphocytic leukemia trial, with …

Curis has consented 10 CLL patients; first five expected to dose by July's end

Curis (NASDAQ: CRIS) announced updated clinical data for emavusertib in Primary CNS Lymphoma (PCNSL) showing a 100% objective response rate in BTK inhibitor (BTKi)-naïve patients and 33% ORR in BTKi-experienced patients. Additionally, the company provided updated enrollment guidance for its TakeAim CLL Phase 2 …

CRSP: CRISPR Therapeutics AG Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for CRISPR Therapeutics AG (CRSP), including its current stock price, market capitalization, volume, and recent performance. It also lists recent news articles related to CRSP and highlights popular discussions on other stocks like HIMS and SPY.

Curis Q2 2026: Updated Clinical Data for Emavusertib Trials

Curis (NASDAQ: CRIS) reported updated clinical data for its emavusertib treatment, showing a 100% objective response rate among five evaluable BTK-naïve lymphoma patients, an increase from 71% in May 2025. The company also expects to dose the first five chronic lymphocytic leukemia patients by …

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) shares surged 11% after the biotechnology company released encouraging updated clinical data for its drug emavusertib in Primary CNS Lymphoma, showing an 86% overall response rate in BTK inhibitor-naïve patients. Regulatory discussions with the FDA and EMA indicate a potential accelerated approval …

Curis stock jumps 11% on positive emavusertib trial data

Curis, Inc. shares surged 11% after announcing positive updated clinical data for emavusertib in Primary CNS Lymphoma, achieving an 86% overall response rate in BTK inhibitor-naïve patients. The company also increased its enrollment guidance for its Chronic Lymphocytic Leukemia study, with plans to dose …

Be Sure To Check Out CRISIL Limited (NSE:CRISIL) Before It Goes Ex-Dividend

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.3% in the first quarter, selling over 104,000 shares, though CRSP remains a significant holding for the firm. Simultaneously, other institutional investors like Hollencrest Capital Management and KBC Group NV …

Crisil Q2FY26 net profit rises 26.2% to ₹216.5 crore

CRISPR Therapeutics stock trades steady as gene-editing pipeline advances after quarterly loss narro

CRISPR Therapeutics stock remained steady as the company narrowed its quarterly losses and advanced its gene-editing pipeline, primarily focusing on sickle cell disease and oncology. The company's financial performance was bolstered by collaboration revenues, which helped offset high research and development costs. Investors are …

Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued?

CRISPR Therapeutics (CRSP) has experienced a significant 61% decline in its stock price over the past five years, prompting an evaluation of its current valuation. Despite the sharp drop, the stock is currently assessed as being in "about right" territory rather than clearly undervalued …

Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path?

Earlier this week, CRISPR Therapeutics AG drew attention as analysts projected an earnings per share of US$1.10 loss alongside very large year-over-year revenue growth for its upcoming results. This combination of improving earnings expectations and strong sales momentum has sharpened the focus on how …

(CRSP) and the Role of Price-Sensitive Allocations

This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP), highlighting weak sentiment across all horizons which supports a short bias. It outlines an exceptional 47.4:1 risk-reward short setup targeting a 14.0% downside. The analysis also provides institutional trading strategies, including long, momentum breakout, and risk …

CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns

CRISPR Therapeutics (CRSP) shares have dropped 10.4% as the market anticipates an earnings report showing improved EPS and significant year-over-year revenue growth. Despite these positive projections, concerns persist regarding the company's operating performance, financial health, and high valuation, leading investors to re-evaluate its position. …

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

CRISPR Therapeutics AG (CRSP) experienced a decline of -1.63% in its latest trading session, underperforming the broader S&P 500. Shares have depreciated by 10.21% over the past month, trailing both the Medical sector and the S&P 500. Investors are anticipating upcoming earnings, with projected …

Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash?

CRISPR Therapeutics (CRSP) stock, despite a 60% decline over five years, now appears to be at a fair valuation, not clearly cheap or expensive. With strong cash reserves of $2.4 billion and a growing gene editing pipeline, the company faces uncertainty regarding the commercial …

Equity in earnings of Curis, Inc. – SWB:CUS1

The article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its equity in earnings, with data sourced from ICE Data Services and FactSet. It indicates that the market for this stock is currently closed, with no trades reported.

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

India Inc's revenue growth to hit 2-year high of 11-11.5% in Q1 despite Iran war: Crisil

REG - CRISM Therapeutics - Holding(s) in Company

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

CRISM Therapeutics Corporation Auditor Raises 'Going Concern' Doubt

Do CRISIL's (NSE:CRISIL) Earnings Warrant Your Attention?

CRISIL Share Price Target 2026: Rs 4,950 Analyst Forecast

Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?

Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates